Captor Capital Valuation

Is NMV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NMV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NMV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NMV's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NMV?

Key metric: As NMV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NMV. This is calculated by dividing NMV's market cap by their current earnings.
What is NMV's PE Ratio?
PE Ratio	0.1x
Earnings	CA$19.36m
Market Cap	CA$2.78m

NMV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does NMV's PE Ratio compare to its peers?

The above table shows the PE ratio for NMV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.8x
2FJ0 Pierrel	29.9x	n/a	€92.8m
PSG PharmaSGP Holding	15.4x	13.9%	€280.6m
93M1 MPH Health Care	0.9x	-65.7%	€105.3m
524606 Beryl Drugs	49x	n/a	₹166.1m
NMV Captor Capital	0.1x	n/a	€2.8m

Price-To-Earnings vs Peers: NMV is good value based on its Price-To-Earnings Ratio (0.1x) compared to the peer average (23.8x).

Price to Earnings Ratio vs Industry

How does NMV's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	20.3x	21.6%
NMV Captor Capital	0.1x	n/a	US$1.99m

2 Companies		Estimated Growth	Market Cap
Industry Avg.	20.3x	21.6%
NMV Captor Capital	0.1x	n/a	US$1.99m

No more companies

Price-To-Earnings vs Industry: NMV is good value based on its Price-To-Earnings Ratio (0.1x) compared to the European Pharmaceuticals industry average (20.3x).

Price to Earnings Ratio vs Fair Ratio

What is NMV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NMV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	0.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NMV's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

-4.3%

91.5%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

-1.8%

0.2%